A private biologics company needed a CRO with a dedicated oncology team to manage its Phase I, multi-center study to evaluate the safety and pharmacokinetic (PK) profile of an immunotherapeutic drug in subjects with advanced solid tumors. The senior director of clinical operations was searching for an oncology-experienced clinical trial partner that could support protocol design and accelerate the start-up process to meet a quick first-patient-in (FPI) milestone. Following a competitive review, the sponsor selected IQVIA Biotech based on our ability to deliver adaptive trial design, demonstrated oncology expertise, flexibility, and understanding of nuanced immunotherapy drug trials.